$132 Million is the total value of Altium Capital Management LP's 68 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 2.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KDNY | CHINOOK THERAPEUTICS INC | $11,718,100 | +66.0% | 305,000 | 0.0% | 8.87% | +126.3% | |
| ASTRIA THERAPEUTICS INC | $11,221,243 | -37.4% | 1,347,088 | 0.0% | 8.49% | -14.6% | ||
| XTNT | XTANT MED HLDGS INC | $5,791,007 | +45.9% | 6,227,559 | 0.0% | 4.38% | +98.9% | |
| AMYLYX PHARMACEUTICALS INC | $3,990,450 | -26.5% | 185,000 | 0.0% | 3.02% | +0.2% | ||
| DYN | DYNE THERAPEUTICS INC | $1,743,750 | -2.3% | 155,000 | 0.0% | 1.32% | +33.2% | |
| PEPPERLIME HEALTH ACQUSTN CO | $1,045,000 | +2.6% | 100,000 | 0.0% | 0.79% | +40.0% | ||
| WESTERN ACQSTN VENTURES CORP | $1,041,000 | +2.0% | 100,000 | 0.0% | 0.79% | +39.0% | ||
| FATBW | FAT BRANDS INC*w exp 07/16/202 | $776,340 | -13.4% | 227,000 | 0.0% | 0.59% | +18.1% | |
| DOUBLEDOWN INTERACTIVE CO LTads | $582,583 | +19.9% | 60,876 | 0.0% | 0.44% | +63.3% | ||
| CLBR | COLOMBIER ACQUISITION CORPcl a | $513,500 | +1.4% | 50,000 | 0.0% | 0.39% | +38.4% | |
| OPY ACQUISITION CORP I | $512,000 | -0.1% | 50,000 | 0.0% | 0.39% | +36.1% | ||
| GOEDWS | POLISHED COM INC*w exp 06/02/202 | $396,138 | -34.4% | 6,103,824 | 0.0% | 0.30% | -10.4% | |
| WEARABLE DEVICES LTD*w exp 09/14/202 | $282,320 | +45.8% | 1,411,600 | 0.0% | 0.21% | +98.1% | ||
| GOED | POLISHED COM INC | $264,982 | -11.6% | 576,048 | 0.0% | 0.20% | +21.1% | |
| DIRECT DIGITAL HOLDINGS INC*w exp 02/15/202 | $108,000 | -20.0% | 180,000 | 0.0% | 0.08% | +9.3% | ||
| NEXGEL INC*w exp 12/01/202 | $97,200 | +178.7% | 225,000 | 0.0% | 0.07% | +289.5% | ||
| CINGULATE INC*w exp 12/10/202 | $56,700 | +22.7% | 270,000 | 0.0% | 0.04% | +65.4% | ||
| ONFOLIO HOLDINGS INC*w exp 01/02/202 | $40,000 | +42.4% | 200,000 | 0.0% | 0.03% | +87.5% | ||
| BRUUSH ORAL CARE INC*w exp 08/03/202 | $28,846 | -33.3% | 360,579 | 0.0% | 0.02% | -8.3% | ||
| NLSPW | NLS PHARMACEUTICS LTD*w exp 02/02/202 | $21,400 | -28.7% | 200,000 | 0.0% | 0.02% | -5.9% | |
| CLBRWS | COLOMBIER ACQUISITION CORP*w exp 99/99/999 | $12,791 | +254.8% | 16,666 | 0.0% | 0.01% | +400.0% | |
| CEA INDUSTRIES INC*w exp 02/11/202 | $13,188 | -33.5% | 250,000 | 0.0% | 0.01% | -9.1% | ||
| NEXALIN TECHNOLOGY INC*w exp 09/15/202 | $11,550 | +15.8% | 105,000 | 0.0% | 0.01% | +50.0% | ||
| PROSOMNUS INC*w exp 04/20/202 | $12,075 | -49.1% | 150,000 | 0.0% | 0.01% | -30.8% | ||
| DIGITAL HEALTH ACQUISITION C*w exp 11/02/202 | $9,990 | -21.6% | 150,000 | 0.0% | 0.01% | +14.3% | ||
| PEPPERLIME HEALTH ACQUSTN CO*w exp 10/01/202 | $8,416 | -75.9% | 367,500 | 0.0% | 0.01% | -68.4% | ||
| WESTERN ACQSTN VENTURES CORP*w exp 09/01/202 | $6,090 | -31.6% | 100,000 | 0.0% | 0.01% | 0.0% | ||
| CHAVANT CAPITAL ACQUISITN CO*w exp 99/99/999 | $6,450 | +36.9% | 150,000 | 0.0% | 0.01% | +66.7% | ||
| HARBOR CUSTOM DEVELOPMENT IN*w exp 10/07/202 | $5,720 | -82.4% | 650,000 | 0.0% | 0.00% | -77.8% | ||
| COLISEUM ACQUISITION CORP*w exp 08/22/202 | $4,247 | +3.4% | 28,333 | 0.0% | 0.00% | +50.0% | ||
| HCDIW | HARBOR CUSTOM DEVELOPMENT IN*w exp 05/09/202 | $4,200 | -71.0% | 600,000 | 0.0% | 0.00% | -62.5% | |
| OPY ACQUISITION CORP I*w exp 09/22/202 | $4,255 | -44.5% | 50,000 | 0.0% | 0.00% | -25.0% | ||
| MURPHY CANYON ACQUISITION CO*w exp 01/25/202 | $4,580 | -49.1% | 100,000 | 0.0% | 0.00% | -40.0% | ||
| SELINA HOSPITALITY PLC*w exp 10/27/202 | $4,331 | -57.3% | 101,439 | 0.0% | 0.00% | -50.0% | ||
| TG VENTURE ACQUISITION CORP*w exp 08/15/202 | $4,500 | -50.0% | 200,000 | 0.0% | 0.00% | -40.0% | ||
| SURROZEN INC*w exp 08/01/203 | $4,539 | -44.8% | 82,233 | 0.0% | 0.00% | -40.0% | ||
| TC BIOPHARM HOLDINGS PLC*w exp 02/08/202 | $809 | -57.0% | 18,823 | 0.0% | 0.00% | 0.0% | ||
| RELATIVITY ACQUISITION CORP*w exp 12/15/202 | $0 | – | 100,000 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FAT BRANDS INC | 12 | Q3 2023 | 0.6% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.9% |
| BELLUS HEALTH INC NEW | 10 | Q1 2023 | 4.7% |
| XTANT MED HLDGS INC | 10 | Q3 2023 | 5.1% |
| IVERIC BIO INC | 10 | Q1 2023 | 2.3% |
| MYRIAD GENETICS INC | 10 | Q1 2023 | 2.3% |
| HARBOR CUSTOM DEVELOPMENT IN | 10 | Q3 2023 | 0.1% |
| CRINETICS PHARMACEUTICALS IN | 9 | Q3 2023 | 4.1% |
| CTI BIOPHARMA CORP | 9 | Q1 2023 | 2.6% |
| POLISHED COM INC | 9 | Q2 2023 | 3.4% |
View Altium Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Marpai, Inc. | April 26, 2023 | 1,805,327 | 6.2% |
| Astria Therapeutics, Inc. | February 14, 2023 | 1,355,372 | 5.0% |
| HyreCar Inc. | February 14, 2023 | 1,688,120 | 5.6% |
| Muscle Maker, Inc. | February 14, 2023 | 2,888,085 | 5.0% |
| NeuroBo Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| PALISADE BIO, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| 1847 Goedeker Inc. | February 14, 2022 | 6,103,824 | 5.0% |
| BioRestorative Therapies, Inc. | February 14, 2022 | 200,000 | 5.0% |
| BriaCell Therapeutics Corp. | February 14, 2022 | 900,000 | 4.7% |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | February 14, 2022 | 363,000 | 5.0% |
View Altium Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-08 |
| SC 13G | 2024-02-21 |
| SC 13G | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Altium Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.